Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
- Conditions
- GliosarcomaRecurrent GlioblastomaAnaplastic Gliomas
- Interventions
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Center Trials & Treatment
- Registration Number
- NCT03275558
- Locations
- 🇸🇬
National University Cancer Institute,, Singapore, Singapore
🇭🇰The Hong Kong Cancer Institute, Hong Kong, Hong Kong
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Conditions
- Renal Cell Carcinoma (RCC)
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 129
- Registration Number
- NCT03260894
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇨🇦Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, Ontario, Canada
Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
- Conditions
- Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT03200717
- Locations
- 🇬🇧
Novartis Investigative Site, Preston, United Kingdom
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT03149120
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
- Conditions
- SarcomaRefractory Sarcoma
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 16
- Registration Number
- NCT03139331
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸UCSF Benioff Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT02979899
- Locations
- 🇺🇸
University of Washinton, Seattle, Washington, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸MD Anderson, Houston, Texas, United States
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Conditions
- Clear Cell Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- Target Recruit Count
- 200
- Registration Number
- NCT02960906
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷Hôpital Cochin, Paris, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 49
- Registration Number
- NCT02959554
- Locations
- 🇩🇪
Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie, Essen, Germany
🇦🇹Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Austria
Study With Improved Solubility Pazopanib
- Conditions
- Pharmacokinetics of Pazopanib
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT02810756
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
- Conditions
- Renal Cell CarcinomaMetastatic DiseaseSoft Tissue Sarcoma
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 6
- Registration Number
- NCT02795819
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.